Patent ID: 7538221
Filing Date: 2009-05-26
Classification: A61P,C07D

Abstract:
1. A polymorph of racemic (±)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid hydrochloride, R-(+)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid hydrochloride, S-(−)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid hydrochloride and racemic (±)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid mesylate, R-(+)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)1,4-dihydro-4-oxo-quinoline-3-carboxylic acid mesylate, S-(−)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid mesylate having the formula I and II respectively wherein said polymorph is selected from the group comprising a) a racemic (±)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid hydrochloride polymorph A-3 exhibiting the following X-ray diffraction pattern b) a R-(+)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid hydrochloride polymorph A-3 exhibiting the following X-ray diffraction pattern c) a S-(−)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid hydrochloride polymorph A-3 exhibiting the following X-ray diffraction pattern (2θ): 7.04±0.2°, 7.70±0.2°, 8.06±0.2°, 12.34±0.2°, 12.78±0.2°, 13.64±0.2°, 15.40±0.2°, 16.14±0.2°, 18.69±0.2°, 19.40±0.2°, 20.64±0.2°, 21.84±0.2°, 23.22±0.2°, 26.80±0.2°, 27.88±0.2°, 29.86±0.2°, 32.30±0.2°, 33.36±0.2°, 37.02±0.2°, 39.24±0.2°; d) a S-(−)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid hydrochloride polymorph A-4 exhibiting the following X-ray diffraction pattern e) a racemic-(±)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid mesylate polymorph B-1 exhibiting the following X-ray diffraction pattern f) a R-(+)1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid mesylate polymorph B-1 exhibiting the following X-ray diffraction pattern g) a S-(−)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpipendin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid mesylate polymorph B-1 exhibiting the following X-ray diffraction pattern h) a racemic (±)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid mesylate polymorph B-2 exhibiting the following X-ray diffraction pattern i) a R-(+)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperldin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid mesylate polymorph B-2 exhibiting the following X-ray diffraction pattern j) a S-(−)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid mesylate polymorph B-2 exhibiting the following X-ray diffraction pattern